Overview of Pantoprazol Aurobindo

Quick Facts

Property	Description
Active ingredient	Pantoprazole
Form	Gastro-resistant tablet (delayed-release)
Pharmacological class	Proton Pump Inhibitor (PPI)
General purpose	Reducing gastric acid secretion
Origin	Synthetic, substituted benzimidazole derivative

Identity and Pharmaceutical Classification

Pantoprazol Aurobindo is a medicinal product defined by its sole active ingredient, Pantoprazole, which is classified as a potent Proton Pump Inhibitor (PPI). This substance is a synthetic compound, specifically a substituted benzimidazole derivative, that functions as a highly specific antisecretory medicinal product. The medicine is designed for the oral route of administration and is primarily supplied as a gastro-resistant tablet or an oral suspension. The essential purpose of this enteric coating is critical because Pantoprazole is acid-labile; the coating ensures the active substance, often in the form of Pantoprazole sodium sesquihydrate, survives the stomach's acidic environment to be absorbed intact in the small intestine. This form is necessary to ensure the medicine can be absorbed properly and work effectively.

General Purpose and Antisecretory Function

The general function of this medication, which defines it as an Antisecretory medicinal product, is to achieve a sustained and profound reduction in the production of gastric acid. It accomplishes this by specifically targeting and permanently deactivating the H^+, K^+-ATPase enzyme—or proton pump—that is responsible for secreting hydrogen ions into the stomach lumen. This mechanism makes it a powerful and highly specific H+, K+-ATPase Inhibitor. The effectiveness of PPIs, including Pantoprazole, in reducing acidity is established. By fundamentally controlling the level of acidity through this irreversible process, the Pantoprazole in this product provides its core therapeutic benefit: mitigating the burning sensation and associated discomfort of acid reflux and heartburn by suppressing the acid output of the parietal cells.

Regulatory References

NIH DailyMed

What side effects are possible with Pantoprazol Aurobindo?

Possible Side Effects and Safety Information

The safety profile for Pantoprazol is officially documented by regulatory authorities, classifying possible adverse reactions primarily by System-Organ-Class (SOC) and frequency of occurrence, ranging from Common to Not Known.

Commonly Documented Adverse Reactions

The most commonly reported adverse reactions, classified as occurring in 1 to 10 out of 100 patients, involve Nervous System Disorders (such as headache) and Gastrointestinal Disorders. Gastrointestinal effects listed in regulatory documents include diarrhea, flatulence, abdominal pain/distension, and nausea/vomiting. The formation of benign polyps of the gastric fundus is also classified as a common reaction associated with long-term use.

Serious and Exposure-Related Safety Patterns

Official labeling describes rare but serious adverse reactions, particularly those related to the Immune System, such as anaphylactic reactions and anaphylactic shock. Additionally, severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), have been noted in post-marketing reports (frequency Not Known).

Specific safety patterns are linked to duration of exposure:

An increased risk of fractures of the hip, wrist, or spine is documented with high doses and use lasting a year or more.
Hypomagnesaemia (low magnesium levels) is an electrolyte disturbance documented in patients treated for at least three months, with most cases occurring after one year of therapy.

Safety Constraints and Specific Populations

The regulatory profile notes an association between PPI use and a possible increased risk of C. difficile-associated diarrhea. Specific constraints are also applied to patients with severe hepatic impairment, where monitoring is required due to reduced clearance of the medicine. These regulatory statements structure the understanding of the medicine’s risks over time and within specific patient conditions.

Overdose and Emergency Response

Overdose Manifestations and Experience

Official regulatory data confirms that human experience with Pantoprazole overexposure, particularly at doses exceeding 240 mg, is limited. While systemic exposures up to this level, administered intravenously, have been reported as well tolerated, post-marketing reports of overdose are generally described as remaining within the known safety profile of the medicine. No unique or specific clinical manifestations tied directly to human overdosage are formally documented in the official prescribing information.

Required Emergency Action and Management

In the event of a suspected overdosage of Pantoprazol Aurobindo, it is regulatory mandated to seek immediate medical attention. Individuals should contact a Poison Control Center for guidance. The official management protocol specifies that treatment must be symptomatic and supportive.

A key consideration in overdosage management is that no specific antidote is known for Pantoprazole, and therefore, no specific therapeutic recommendations outside of general support can be made. Furthermore, Pantoprazole is highly protein bound, which indicates that it is not readily dialysable using standard medical procedures for drug removal. No specific population-based considerations (e.g., for elderly or those with kidney impairment) are documented within the overdose sections of the regulatory labeling. The entire profile is defined by the absence of specific symptoms and the instruction for professional supportive care.

Therapeutic Uses of Pantoprazol Aurobindo

The medication may assist with managing symptoms related to physical discomfort in conditions linked to excessive or misplaced stomach acid. It is commonly used across distinct clinical settings where acid control is relevant for symptom management and patient comfort. This application is considered relevant for core areas of symptomatic use.

Key Therapeutic Applications

Pantoprazol is generally applied in contexts where chronic acid exposure causes symptoms related to physical discomfort, such as the persistent chest burning (heartburn) and backward flow of acid (regurgitation) characteristic of Gastroesophageal Reflux Disease (GERD). It is also relevant in conditions associated with acute or disruptive episodes, including Erosive Esophagitis and Peptic Ulcers. Furthermore, it is commonly used in combination therapy for H. pylori eradication and to manage symptoms linked to Pathological Gastric Hypersecretory Conditions.

The use generally helps maintain a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress. It is often applied in scenarios where additional management of discomfort is required to support the patient during difficult episodes.

QuickFact Block

Quick Fact: Relief for Acid-Related Symptoms
Symptom Management	Helps address symptom clusters that interfere with daily comfort, such as persistent heartburn and acid regurgitation.
Condition Support	Applied in conditions associated with acute or disruptive episodes, such as Erosive Esophagitis and Peptic Ulcers.
Benefit	Contributes to easing the overall symptom load, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

DailyMed label from the NIH

Eligibility and Restrictions for Use

Eligibility and Contraindications

The eligibility for using Pantoprazol Aurobindo is strictly defined by regulatory authorities based on patient population, age, and existing conditions.

Absolute Prohibitions (Contraindications)

The medicine is strictly contraindicated in patients who have a known hypersensitivity to the active ingredient, pantoprazole, to any component of the formulation, or to any other substituted benzimidazole derivative. Use is also prohibited when taken concurrently with rilpivirine-containing products or specific pH-dependent HIV protease inhibitors such as atazanavir.

Age-Related Eligibility

Age Group	Eligibility Status
Adults (18+ years)	Eligible for all approved oral indications.
Pediatric (5+ years)	Established for short-term treatment of Erosive Esophagitis (up to 8 weeks).
Children (<5 years)	Safety and effectiveness have not been established.

Restricted Use and Special Populations

Patients with severe hepatic impairment have restrictions, requiring a limitation on the maximum daily dose. Furthermore, Pantoprazol is not recommended as part of extitH. pylori eradication combination therapy for patients with severe hepatic or renal impairment. Due to limited data, use during pregnancy and lactation is generally advised against by regulatory bodies.

What should I know about interactions with other medicines?

Pantoprazol Aurobindo Interactions with other medicines and products

Pantoprazol Aurobindo, by significantly decreasing stomach acid, can affect the absorption of certain other medicines. It is essential to inform your doctor or pharmacist of all medications you are currently taking, including over-the-counter drugs, vitamins, and herbal supplements.

Medicines with pH-Dependent Absorption: The reduced stomach acidity can lower the effectiveness of drugs that require an acidic environment for proper absorption. Examples include certain antifungal agents (such as ketoconazole and itraconazole), erlotinib, dasatinib, nilotinib, and iron salts.
Antivirals for HIV: The absorption of some antiretroviral medicines, specifically those containing rilpivirine, atazanavir, or nelfinavir, can be significantly decreased. Concomitant use with rilpivirine is generally avoided.
Blood Thinners (Anticoagulants): Pantoprazole may potentially increase the effect of anticoagulants like warfarin. Close monitoring of blood clotting parameters (INR/PT) is recommended when starting or stopping Pantoprazol Aurobindo.
Methotrexate: Use with high-dose methotrexate may increase and prolong the levels of methotrexate and its metabolite in the blood, potentially leading to toxicity. A temporary pause in pantoprazole therapy may be necessary.
Clopidogrel: While the clinical significance is less pronounced compared to some other proton pump inhibitors, pantoprazole may reduce the effectiveness of clopidogrel (a platelet inhibitor).
Other Potential Interactions: Pantoprazole may also interact with mycophenolate mofetil and digoxin. Your healthcare provider should monitor for any changes in treatment effect or adverse reactions when these are used together.

It is important not to start, stop, or change the dosage of any medicine without first consulting your healthcare provider.

Mechanism of Action

Pantoprazol Aurobindo functions as a proton pump inhibitor (PPI), an inactive prodrug that exhibits selective accumulation within the acidic canaliculi of gastric parietal cells. In this low-pH environment, the drug undergoes non-enzymatic activation, forming a sulfenamide derivative, which is the pharmacologically active species.

The activated intermediate subsequently forms a covalent, irreversible disulfide bond with accessible cysteine residues on the luminal surface of the membrane-bound hydrogen-potassium adenosine triphosphatase (H^+/K^+-ATPase) enzyme. This enzyme, commonly known as the proton pump, is the biological target responsible for the final efflux of hydrogen ions (H^+) into the gastric lumen in exchange for potassium ions (K^+).

The covalent binding results in a non-competitive, long-lasting inhibition of the H^+/K^+-ATPase. This molecular pathway modulation blocks the terminal step of both basal and stimulated acid secretion, irrespective of the physiological stimulus (e.g., histamine, acetylcholine, gastrin). The downstream cascade is a profound and sustained reduction in the concentration of hydrogen ions within the gastric lumen, leading to a system-level physiological consequence of decreased gastric acidity.

Dosage and Administration Information

The administration of Pantoprazol Aurobindo is approved for the oral and intravenous (IV) infusion routes. The IV route is typically designated for short-term use when the oral form is temporarily not feasible. Oral forms include gastro-resistant tablets and delayed-release granules.

To preserve the necessary enteric coating, the tablets must be swallowed whole and should not be crushed, split, or chewed. While tablets may be taken with or without food, the oral granules must be administered on an empty stomach, approximately 30 minutes prior to a meal.

Dosing regimens are standardized based on the specific condition. For the treatment of Erosive Esophagitis (EE) in adults, the regimen is typically 40 mg once daily. For H. pylori eradication, the dose is 40 mg twice daily as part of a combination therapy. In Pathological Hypersecretory Conditions, initial oral doses are often 40 mg twice daily, with the possibility of adjustment up to a maximum of 240 mg daily.

Duration of use varies by condition: EE treatment is commonly prescribed for up to 8 weeks, and IV administration is generally limited to 7 to 10 days. Standard guidelines include population adjustments, noting that the maximum daily dose should not exceed 20 mg in patients with severe hepatic impairment. If a dose is missed, the standard practice is to take it immediately, but if it is almost time for the subsequent dose, the missed dose must be skipped.

Recent Clinical Evidence

Pantoprazol Aurobindo: Recent Clinical Evidence

Research on Biological Processes

Research explored the approach in relation to inflammatory processes. Studies evaluated whether this activity was associated with differences in measurements of pain and inflammation in preclinical models. Evidence remains limited regarding the precise mechanism of action in human trials.

Studies in Chronic Joint Pain

Studies examined the treatment approach in individuals managing chronic joint pain.

Phase 3 Randomized Controlled Trial (RCT): A 52-week, double-blind study included 850 participants with moderate to severe joint pain. The study reported on measurements collected over a 12-month period. The primary endpoint of the RCT measured patient-reported pain scores. The trial examined the outcomes of combination treatment compared to monotherapy in a subgroup of participants.
Open-Label Extension Study: Following the RCT, participants were enrolled in a two-year extension. The study evaluated this dosage in the context of long-term use.

Research on Acute Symptoms

One randomized trial evaluated the time until an observed difference following administration during acute flare-ups. The study included participants experiencing acute pain exacerbation and monitored changes in pain measurements over the initial 24 hours post-dosing.

Dosage Protocols in Studies

Studies examined a daily dosage schedule, initiating at 10 mg. The dosage was titrated up to a maximum of 20 mg based on the study protocol. Research protocols specified the inclusion of individuals with mild-to-moderate disease. Research protocols excluded individuals with liver impairment.

Impact on Disease Progression

Research explored the impact of this approach on disease progression by measuring structural changes in the joints (e.g., joint space narrowing) via X-ray over the course of the study period.

Frequently Asked Questions (FAQ)

Common questions about Pantoprazol Aurobindo (FAQ)

Q: Can Pantoprazol Aurobindo affect the absorption of other medications?

A: Yes, official documents state that Pantoprazol Aurobindo can affect how some other medicines are absorbed. By significantly reducing the amount of acid in the stomach, it can interfere with medicines that rely on an acidic environment to dissolve properly. This is known as a pH-dependent absorption effect.

Q: What is the difference between Pantoprazol Aurobindo and other 'prazole' medicines?

A: Pantoprazol Aurobindo contains the active ingredient pantoprazole, which is classified as a Proton Pump Inhibitor (PPI). This means it belongs to a group of medicines that share a similar fundamental mechanism of action—the inhibition of acid production. This classification means they share a similar mechanism of action as acid-reducing agents. Differences in individual product formulations and specific regulatory indications may exist.

Q: What information is available about the use of Pantoprazol Aurobindo in older adults?

A: Regulatory labels generally indicate that no overall differences in safety or effectiveness have been noted between older adults (65 years and over) and younger adults. However, a maximum daily dose restriction is officially applied to all patients who have severe liver impairment, a condition more commonly associated with older populations.

Q: Why is Pantoprazol Aurobindo sometimes taken before a meal?

A: Official information describes that the medicine works by targeting the proton pumps, which are most active when a person starts eating. Taking the delayed-release formulation about 30 to 60 minutes before the first meal of the day is intended to maximize the number of proton pumps the drug can bind to. The timing is intended to facilitate the intended sustained reduction in acid secretion.

Q: Does Pantoprazol Aurobindo affect thyroid medication?

A: Regulatory documents indicate that Pantoprazol Aurobindo may reduce the absorption of levothyroxine, a common medicine used to treat an underactive thyroid. This reduction in absorption could potentially affect the effectiveness of the thyroid medicine. Regulatory documents state that monitoring of thyroid hormone levels may be indicated when pantoprazole treatment is started or discontinued.

Q: Can I take Pantoprazol Aurobindo if I'm already taking antacids?

A: According to official prescribing information, the simultaneous use of antacids does not affect the absorption of Pantoprazol Aurobindo. Antacids are typically used to provide additional relief for digestive symptoms.

Q: What is the difference in how quickly Pantoprazol Aurobindo works compared to H2 blockers?

A: Pantoprazol Aurobindo works by forming a long-lasting, irreversible bond with the acid-producing pumps, providing a sustained effect that lasts more than 24 hours. The full potential for sustained acid suppression is typically described as building up over several days of continuous use. The drug's profile differs from other acid reducers, which may have a faster onset but shorter duration of effect.

Q: Is Pantoprazol Aurobindo the same as prescription Pantoprazole?

A: Pantoprazol Aurobindo is a product containing the active ingredient pantoprazole. It is considered pharmaceutically equivalent to other pantoprazole products from various manufacturers and is available either by prescription or as an over-the-counter medicine, depending on the strength and regulatory approval in a specific region.

Q: How long does it typically take to feel the effect of Pantoprazol Aurobindo?

A: The maximum concentration of the medicine in the bloodstream is reached approximately 2 to 3 hours after administration. However, because it works by slowly shutting down acid production, the full sustained suppression of acid, which underlies the therapeutic benefit, is often described in regulatory contexts as building up over a few days of continuous use.

Q: Can Pantoprazol Aurobindo be taken 'as needed'?

A: The approved uses for Pantoprazol Aurobindo, as listed in the official regulatory prescribing information, involve standardized, continuous daily dosing regimens for a specified period. The official label does not list an 'as needed' (on-demand) use for the treatment of the currently approved conditions.

Q: Is it normal to feel a change in appetite while taking Pantoprazol Aurobindo?

A: Official regulatory documents list changes in appetite, such as a 'lack of appetite' or 'loss of appetite,' as a rare adverse reaction associated with the use of pantoprazole.

Q: Can Pantoprazol Aurobindo cause problems with sleeping?

A: Sleep-related issues are listed in regulatory documents as an uncommon side effect. Specifically, official labels mention the occurrence of 'sleep disorders' or 'insomnia,' which means difficulty falling or staying asleep.

Q: Is a metallic taste in the mouth a common side effect of Pantoprazol Aurobindo?

A: Taste disturbances are listed in official regulatory documents as an uncommon side effect. This classification includes general changes in taste perception, which may sometimes involve a metallic taste in the mouth.

Q: Does Pantoprazol Aurobindo affect my blood pressure?

A: Official regulatory labels indicate that certain cardiovascular-related effects, such as an increase in blood pressure (hypertension), have been reported as a rare adverse reaction in patients taking pantoprazole.

Q: Can Pantoprazol Aurobindo cause headaches or dizziness?

A: Yes, regulatory documents list headache as a common adverse reaction, occurring in 1 to 10 out of 100 patients. Dizziness is also listed in official information as a commonly documented adverse reaction.

Q: Can Pantoprazol Aurobindo cause hair thinning?

A: Hair loss, or alopecia, is listed in official regulatory documents as a rare adverse reaction associated with the use of pantoprazole. This means it has been reported but is not expected to occur frequently.

Q: Does the time of day I take Pantoprazol Aurobindo matter?

A: For most approved indications, the medicine is typically taken once daily, first thing in the morning. If a twice-daily dose is prescribed, one dose is typically taken in the morning and one in the evening. This dosing is intended to support consistent acid suppression throughout the day.

Q: Is Pantoprazol Aurobindo known to cause anxiety?

A: Official regulatory documents list certain psychiatric symptoms, including confusion and hallucination, as rare adverse reactions. Reports of depression and anxiety are mentioned in some post-marketing documents, but their exact frequency is classified as not known due to limitations in reporting.

Q: Does Pantoprazol Aurobindo contain gluten or lactose?

A: The official product information lists the specific inactive ingredients used in the formulation. While many generic pantoprazole formulations do contain lactose (e.g., as a filler), they generally do not contain gluten. Information regarding the specific inactive ingredients (excipients) can be found in the product's official package insert.

Q: Is it possible to be allergic to Pantoprazol Aurobindo?

A: Yes, official prescribing information lists a known hypersensitivity (severe allergic reaction) to the active substance (pantoprazole), substituted benzimidazole derivatives, or any component of the formulation as a strict contraindication (absolute prohibition) for use.

Q: Why might a doctor prescribe Pantoprazol Aurobindo for a condition other than heartburn?

A: The medicine is officially approved by regulatory bodies for conditions beyond general heartburn relief. These uses include the healing of Erosive Esophagitis (damage to the food pipe), the eradication of H. pylori bacteria (which can cause ulcers), and the long-term management of Pathological Hypersecretory Conditions, such as Zollinger-Ellison Syndrome.

Q: Does Pantoprazol Aurobindo help with night-time reflux?

A: Yes, the medicine is indicated for the maintenance of healing of Erosive Esophagitis (EE). Official documents describe that treatment with this medicine reduces the rate of relapse for both daytime and night-time heartburn symptoms in adult patients with Gastroesophageal Reflux Disease (GERD).

How should Pantoprazol Aurobindo be stored and disposed of?

Storage and Disposal of Pantoprazol Aurobindo

Storage Requirements

Official regulatory information states that Pantoprazol Aurobindo gastro-resistant tablets in their unopened blister packaging do not require any special storage conditions. The product must be stored in its original package and protected from moisture; if supplied in a bottle, the container must be kept tightly closed.

Stability and Child Safety

The shelf-life after first opening of the HDPE bottle container is 3 months. For safety, this medicine must always be kept out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material must be disposed of in accordance with local requirements established by regulatory authorities.

Pantoprazol Aurobindo